Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Apple's growth these days is a bit modest, as revenue for the last three months of 2024 was up just 4%, but it still has ...

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Cannell & Spears LLC boosted its stake in Regeneron Pharmaceuticals by 50.9% last quarter, grabbing 5,415 more shares and ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regeneron (REGN – Research Report) and TG ...

UniSuper Management Pty Ltd turned up the financial charm, upping its Regeneron stake by 38% in Q4. The fund now owns 7,306 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

Cash or stock dividends that are distributed to shareholders aren't recorded as an expense on a company's income statement. Cash and stock dividends don't affect a company's net income or profit.